In a Nutshell
BPC-157 is not FDA-approved, and no controlled human trial has established that it heals tendon, muscle or gut tissue — the substantial literature behind it is almost entirely in animals.
BPC-157 is the most-searched peptide in the wellness market, and it sits on the largest gap between reputation and evidence of anything in this category.
The animal literature is genuinely substantial — more than 200 peer-reviewed studies, mostly in rats, reporting effects on tendon, ligament, muscle and gut tissue healing. The human literature is not — though the accurate version of that statement is narrower than the one usually made.
One randomized controlled trial in humans does exist. FDA's own briefing document for the July 2026 meeting identifies a multicenter, randomized, double-blind, placebo-controlled study in ulcerative colitis (Ruenzi et al., 2005): 53 subjects with mild-to-moderate UC randomized 1:1 to BPC-157 (as PL 14736) 80 mg enema or placebo, once daily for two weeks, with 46 completing 1.
Three things limit what it can support. It was published only as a meeting abstract, with the disease definition, inclusion criteria and primary endpoint insufficiently specified for reliable interpretation. It is twenty years old and has not been replicated. And it studied a rectal enema for a bowel disease — which tells you very little about injecting BPC-157 for tendon or muscle healing, the use it is overwhelmingly marketed for.
So the defensible statement is: no adequately reported, peer-reviewed randomized trial has established that BPC-157 is effective for any indication. A registered Phase II trial in hamstring injury (NCT07437547) began recruiting in February 2026 — a registered Phase 2 musculoskeletal RCT (hamstring strain), not the first human trial 3.
BPC-157 is not an FDA-approved drug. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8–6, with one abstention, to recommend adding BPC-157 free base and BPC-157 acetate to the 503A Bulks List, evaluated in the context of proposed use for ulcerative colitis. That was contrary to the conclusions presented by FDA staff reviewers, who found a lack of evidence supporting effectiveness and noted the substance is not well characterized 4.
The recommendation is non-binding. It is not drug approval, it does not itself authorize compounding, it says nothing about 503B outsourcing-facility eligibility, and FDA must complete the applicable rulemaking before anything is added to the list. FDA has not done so.
This page exists because the question is asked constantly and most of what ranks for it is written by people selling the product.
What BPC-157 Is
BPC-157 — "Body Protection Compound 157" — is a synthetic chain of 15 amino acids. It is described as a partial sequence derived from a protein found in human gastric juice, though this framing is more marketing-friendly than precise: BPC-157 as sold is a laboratory-synthesized peptide, not something extracted from the body.
It is used mainly with the aim of tissue and gut healing and recovery: recovery from training and injury, tendon and ligament problems, and gut symptoms. It is often combined with TB-500, and sometimes with GHK-Cu and KPV in blends marketed as "GLOW" and "KLOW".
Its proposed mechanisms are hypotheses drawn from preclinical work, not a characterized human mechanism — FDA states BPC-157's molecular targets have not been identified and its mechanisms remain poorly understood. With that caveat, the proposed mechanisms center on angiogenesis (formation of new blood vessels), modulation of growth-factor signaling in healing tissue, and effects on nitric oxide pathways. In rodent models these have been associated with faster healing of tendon, ligament, muscle and gastrointestinal tissue.
Two cautions on that literature. First, rodent healing physiology differs substantially from human healing, and injectable rodent studies often use dosing that does not translate directly. Second, an unusually high proportion of the published work originates from a small number of affiliated investigators — which is not by itself evidence of a problem, but does mean the findings have not been broadly independently replicated.
Current FDA and Compounding Status
BPC-157 is not approved by FDA for any use.
BPC-157 previously sat in 503A Category 2. After the nominators withdrew their nominations, FDA removed it from that category — but retained its published safety-risk summary, and then elected on its own initiative to evaluate BPC-157 free base and BPC-157 acetate for possible inclusion on the 503A Bulks List 5.
That last point matters, and it corrects a natural misreading: BPC-157 did not simply drop out of review. FDA chose to keep looking at it. Reports that FDA "cleared" or "reinstated" it are wrong in the other direction. Removal from Category 2 does not by itself make a substance eligible for compounding. Eligibility runs through one of three statutory routes — a USP/NF monograph, being a component of an FDA-approved drug, or the 503A Bulks List — and every other 503A requirement still has to be met.
FDA's stated concern on BPC-157 is that compounded preparations "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient characterization," and that the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans" 5.
That is a statement about missing data, not about demonstrated harm — a distinction that is easily blurred in both directions.
The July 2026 advisory vote is covered in full on our FDA peptide status page, which is updated as FDA acts.
What the Evidence Actually Shows
This is where BPC-157 differs most from how it is marketed.
| Claim commonly made | What the evidence supports |
|---|---|
| Heals tendons and ligaments | Rodent studies report this. No human trial has tested it; the one human RCT studied an enema for colitis. |
| Repairs the gut lining | Rodent models, plus one abstract-only 53-subject RCT of an enema formulation too poorly reported to interpret. |
| Reduces inflammation | Animal data. Human data absent. |
| Accelerates injury recovery | No controlled human evidence. A registered trial (NCT07437547) began recruiting Feb 2026. |
| "Thousands of studies prove it works" | 200+ studies exist — overwhelmingly preclinical animal work. |
Evidence tier: C. The honest summary is that BPC-157 has an interesting preclinical profile and a human evidence base of five small studies — rectal, intra-articular, intravesical and intravenous — of which only one was a randomized controlled efficacy trial, abstract-only, of a different formulation for a different problem. That is not the same as saying it does not work — it may. It means nobody has yet done the work that would let anyone say so responsibly.
The distinction matters practically: preclinical promise frequently fails to survive controlled human testing. That is the ordinary outcome in drug development, not an unusual one.
Safety, Side Effects and What Is Unknown
Very little is known about BPC-157's safety profile in humans — but the record is more informative than "unknown."
FDA identified five small human studies using rectal, intra-articular, intravesical and intravenous administration. No serious adverse events were reported in them, but they were short, involved few participants and provided limited safety monitoring. FDA identified no human study using the proposed subcutaneous route — the one that is marketed.
FDA also retrieved three adverse-event reports involving injectable products: an injection-site reaction, shortness of breath, and hyperpigmentation with gingival darkening after a BPC-157/TB-500 blend. These establish neither incidence nor causality; in two, attribution to BPC-157 was limited or impossible. Short animal repeat-dose studies produced clotting and liver-associated findings whose relevance to humans and to marketed routes is unknown.
The correct conclusion is not that BPC-157 has been shown dangerous. It is that its human safety profile — particularly for repeated subcutaneous use — cannot be characterized from what exists.
The specific unknowns worth understanding:
- Long-term safety — no long-duration human data exists
- Carcinogenicity: unstudied. No carcinogenicity study has been conducted, and no human cancer signal has been established. FDA has not identified BPC-157's molecular targets and states its mechanisms remain poorly understood — so the usual angiogenesis-to-cancer argument has no firm footing at either end. Long-term risk cannot be quantified, but current evidence does not support a BPC-157-specific cancer warning, a family-history rule, or a cancer-symptom checklist. Anyone in active cancer treatment or oncology surveillance should discuss any unapproved product with their oncologist
- Immunogenicity — FDA's stated concern: peptide aggregation and related impurities can provoke immune responses 5
- Drug interactions — essentially unstudied
- Pregnancy and breastfeeding — no data; should not be used
- Kidney and liver effects — a common search question. There is no established evidence of kidney or liver toxicity in humans, but "no established evidence" here reflects an absence of studies rather than reassuring findings
Product-related risk is separate from substance-related risk, and for BPC-157 it may be the larger of the two. Most BPC-157 in circulation is sold as a research chemical with no sterility, potency or identity requirement — meaning the realistic risks include injection-site infection, incorrect dose, and a vial that does not contain what the label says. See peptide sourcing and quality.
Red Flags — Seek Care Now
Call 911 now for difficulty breathing, facial or throat swelling, fainting, severe chest pain, confusion, or a sudden severe headache with weakness, speech difficulty or vision loss. Seek same-day assessment for fever with spreading injection-site redness, warmth, pus, red streaking or rapidly increasing swelling. Arrange prompt evaluation for anything else below.
Specifically:
- Fever, spreading redness, warmth, swelling or pus at an injection site — possible injection-site infection
- Difficulty breathing, facial or throat swelling, widespread hives — possible allergic reaction; call 911
- Chest pain, fainting, severe breathlessness or severe persistent abdominal pain — seek urgent care regardless of suspected cause, and tell the clinician exactly what product you used. These are general emergency symptoms, not established BPC-157-specific effects
Tell any treating clinician that you have used it. They cannot assess you properly without knowing, and disclosure is far more useful than discretion here.
Why Athletes Need to Check Separately
BPC-157 is prohibited under the World Anti-Doping Agency framework, and the legal and disciplinary basis differs between governing bodies such as USADA and the NCAA. This is independent of FDA status — a substance can be prohibited in competition regardless of its regulatory position.
If you compete under any anti-doping code, confirm current status with your governing body directly before using anything in this category.
On Dosing
BPC-157 dosing is among the most-searched aspects of this peptide. This page does not provide dosing protocols, and that is deliberate rather than evasive.
No validated subcutaneous regimen has been established for tendon, muscle or injury recovery. Human subjects have received BPC-157 rectally, intra-articularly, intravesically and intravenously — but those doses cannot be converted into a subcutaneous protocol, and no controlled dose-ranging study links any marketed regimen to a meaningful clinical outcome.
Protocols circulating online are extrapolated from rodent studies or copied between forums, and are applied to products whose actual concentration is unverified. The combination — an unvalidated dose of an unverified preparation, self-administered without monitoring — is precisely the risk that clinical supervision exists to manage.
If you are determined to proceed regardless, the single most useful thing you can do is tell your clinician, so that someone with training is aware and watching.
What You Can Do About It
If your underlying goal is faster recovery from injury, better tendon or joint function, or gut symptoms, those are real clinical problems with real assessment pathways — and several have treatments with actual human evidence behind them.
- Persistent tendon or joint pain warrants diagnosis before treatment. "Tendinopathy" covers several distinct problems with different management
- Gut symptoms merit evaluation. Inflammatory bowel disease, celiac disease and other conditions have specific, evidence-based treatments — and BPC-157's proposed colitis indication is exactly the space where self-treatment can delay a diagnosis that matters
- Slow recovery generally is often downstream of something measurable: thyroid function, testosterone and other hormones, vitamin D, iron studies, sleep quality, protein intake, or body composition
Get Started with JumpstartMD
JumpstartMD was founded in 2007 by Stanford-trained physicians, and our programs are built around labs, hormones and body composition rather than any single product. You are seen face-to-face by licensed clinicians — in person at 14 California locations or online across California — with a clinical assessment that includes 60-biomarker lab screening and InBody® body composition scanning. If slow recovery, poor sleep or body-composition change is what brought you here, that assessment can identify some contributors and indicate when targeted injury evaluation, imaging or specialist referral is needed — it cannot determine every cause from laboratory testing alone. InBody scans are done in clinic; online members can book one at any of the 14 locations.
Can you get BPC-157 from a doctor?
BPC-157 is not an FDA-approved drug, and FDA has not acted on the July 2026 advisory recommendation regarding its eligibility for compounding.
If the symptom or goal that led you here has not been evaluated, our clinicians can assess the relevant causes and evidence-based options — that assessment does not assume another peptide is the answer. Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- Are Peptides Legal in the US? The FDA Status, Explained — what the July 2026 vote decided, updated as FDA acts
- How to Tell If a Peptide Is Legitimate — why most BPC-157 in circulation carries no quality assurance
- TB-500 — the peptide most often stacked with BPC-157, and its own evidence position
- Peptide Therapy: What It Is and Who It's For — the overview
Frequently Asked Questions
Is BPC-157 FDA approved?
No. BPC-157 is not approved by FDA for any indication. On July 23, 2026 an FDA advisory committee voted 8 yes / 6 no / 1 abstention on each form to recommend adding it to the 503A Bulks List for compounding for ulcerative colitis, contrary to the conclusions presented by FDA staff reviewers. FDA has not acted on that recommendation, and eligibility for pharmacy compounding would not be the same as approval as a drug.
Does BPC-157 actually work?
In animals, the evidence is substantial and fairly consistent. In humans, one randomized, double-blind, placebo-controlled study exists — 53 subjects, an 80 mg enema for ulcerative colitis, published only as a meeting abstract. Its incomplete reporting and route make it inadequate to establish efficacy. FDA identified five small human studies overall, and none establishes injected BPC-157 for tendon, muscle or injury recovery. NCT07437547 is a registered Phase 2 musculoskeletal RCT (hamstring strain) — not the first human trial. Anyone telling you it is proven to work in humans is going beyond the published evidence.
Is BPC-157 hard on the kidneys?
There is no established evidence of kidney toxicity from BPC-157 in humans — but that reflects a near-total absence of human safety studies rather than reassuring findings. Separately, non-sterile or mislabeled research-grade products carry their own risks. If you have existing kidney disease, this is a conversation to have with your clinician before considering anything in this category.
Can you take BPC-157 every day?
No validated subcutaneous dosing schedule exists. Human exposure has occurred by other routes, but those doses do not transfer, and circulating protocols are extrapolated from animal work. This page does not provide dosing guidance.
Can you buy BPC-157 over the counter?
No. BPC-157 is not an approved over-the-counter product. Products sold online are typically labeled "research use only / not for human use." That labeling does not make the sale lawful or the product lawful for human use — FDA judges intended use from how a product is actually marketed — but it does tell you the product has not been shown to meet sterility, potency or identity requirements.
What is the difference between BPC-157 and TB-500?
They are distinct peptides with different proposed mechanisms — BPC-157 acting largely on angiogenesis and growth-factor signaling, TB-500 (a thymosin beta-4 fragment) on cell migration and actin regulation. They are frequently sold as a combined "recovery stack." Neither is FDA-approved, both received favorable advisory votes in July 2026, and neither has an adequately reported, peer-reviewed randomized trial establishing efficacy (BPC-157 has one abstract-only 2005 enema trial in colitis; TB-500 has none).
Is BPC-157 banned in sport?
Yes. It is prohibited under WADA rules and by organizations following them, including USADA and the NCAA. This applies regardless of its FDA status. Confirm current status with your governing body directly.
Is BPC-157 safe?
The honest answer is that nobody knows. FDA's own position is that it lacks sufficient information to determine whether it would cause harm in humans. Reported tolerability in very small pilot work has been unremarkable, but those studies are far too small and short to establish safety. On top of that, most product in circulation is unregulated, which introduces risks of contamination and incorrect dosing independent of the substance itself.
References
- U.S. Food and Drug Administration, "BPC-157 — Briefing Document, Pharmacy Compounding Advisory Committee," Jul. 2026. [Online]. Available: https://www.fda.gov/media/193343/download [Accessed: Jul. 25, 2026]. ↩
- InpharmD, "Is BPC-157 safe for use in humans? Is there evidence that BPC-157 use in humans facilitates muscle and tendon healing?" [Online]. Available: https://inpharmd.com/inquiries/13701 [Accessed: Jul. 25, 2026]. ↩
- Hudson Biotech, "BPC 157 for Acute Hamstring Muscle Strain Repair (A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI)," ClinicalTrials.gov identifier NCT07437547, first posted Feb. 27, 2026. [Online]. Available: https://clinicaltrials.gov/study/NCT07437547 [Accessed: Oct. 5, 2026]. ↩
- Regulatory Affairs Professionals Society, "FDA advisory committee backs two controversial peptides," Jul. 2026. [Online]. Available: https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html [Accessed: Jul. 25, 2026]. ↩
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- The Hill, "FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists," Jul. 2026. [Online]. Available: https://thehill.com/homenews/5987510-fda-committee-votes-peptides/ [Accessed: Jul. 25, 2026]. ↩
- World Anti-Doping Agency, "The 2026 Prohibited List — World Anti-Doping Code International Standard," effective Jan. 1, 2026, §S0 Non-approved substances. [Online]. Available: https://www.wada-ama.org/en/prohibited-list [Accessed: Oct. 5, 2026]. ↩
- D. Gwyer, N. M. Wragg, S. L. Wilson, "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing," Cell and Tissue Research, vol. 377, no. 2, pp. 153-159, Aug. 2019, [Online]. Available: https://doi.org/10.1007/s00441-019-03016-8. PMID: 30915550. [Accessed: Jul. 25, 2026]. ↩
- N. Vasireddi, H. Hahamyan, M. J. Salata, M. Karns, J. G. Calcei, J. E. Voos, J. M. Apostolakos, "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS Journal: the Musculoskeletal Journal of Hospital for Special Surgery, vol. 21, no. 4, Jul. 2025, [Online]. Available: https://doi.org/10.1177/15563316251355551. PMID: 40756949. [Accessed: Jul. 25, 2026]. ↩